Scholar Rock Holding (SRRK) EBT (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly EBT of -$101.4 million for Q1 2026, down 35.42% year-over-year from -$157.1 million in Q1 2025, and down 11.21% quarter-over-quarter from -$91.2 million in Q4 2025.
Scholar Rock Holding (SRRK) EBT (2017 - 2026) Analysis & Trends
Scholar Rock Holding's EBT history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.
- In Q1 2026, EBT fell 35.42% year-over-year to -$101.4 million; the TTM figure through Mar 2026 stood at -$717.0 million (down 168.23% YoY), while the FY2025 annual figure was -$377.7 million, down 53.37% from the prior year.
- EBT for Q1 2026 stood at -$101.4 million, down from -$91.2 million in the prior quarter.
- The five-year high for EBT was -$9.2 million in Q1 2022, with the low at -$263.8 million in Q2 2025.
- The 5-year median for EBT is -$56.8 million (2024), against an average of -$80.3 million.
- The sharpest annual moves came in 2022 and 2023: EBT soared 93.69% in 2022, then plunged 383.1% in 2023.
- Scholar Rock Holding's EBT stood at -$42.1 million in 2022, then slipped by 18.84% to -$50.0 million in 2023, then sank by 32.75% to -$66.4 million in 2024, then sank by 37.37% to -$91.2 million in 2025, then declined by 11.21% to -$101.4 million in 2026.
- Business Quant data shows SRRK's EBT at -$101.4 million in Q1 2026, -$91.2 million in Q4 2025, and -$260.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | -311.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -311.33 Mn |
| Mar 31, 2026 | -101.45 Mn |
| Dec 31, 2025 | -91.23 Mn |
| Sep 30, 2025 | -260.46 Mn |
| Jun 30, 2025 | -263.83 Mn |
| Mar 31, 2025 | -74.91 Mn |
| Dec 31, 2024 | -66.41 Mn |
| Sep 30, 2024 | -65.66 Mn |
| Jun 30, 2024 | -60.31 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -50.03 Mn |
| Sep 30, 2023 | -46.00 Mn |
| Jun 30, 2023 | -42.09 Mn |
| Mar 31, 2023 | -44.43 Mn |
| Dec 31, 2022 | -42.10 Mn |
| Sep 30, 2022 | -46.45 Mn |
| Jun 30, 2022 | -43.90 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -87.69 Mn |